The University of Glasgow Pontecorvo Team Presents their Work at ASHG 2024.
Published: 12 November 2024
The University of Glasgow Pontecorvo team (Dr Nhu Ngoc Le, Dr Stefanie Lip, Mr Quoc Bao Tran Tran) presented their significant findings in their pharmacogenomics research at the American Society of Human Genetics Conference, Denver, Colorado.
At the 2024 American Society of Human Genetics Conference, Denver, Colorado conference (5-9th November 2024), the University of Glasgow Pontecorvo team (Dr Nhu Ngoc Le, Dr Stefanie Lip, Mr Quoc Bao Tran Tran) had the opportunity to present significant findings in their pharmacogenomics research. The research was supervised by Professor Sandosh Padmanbhan, Pontecorvo Chair of Pharmacogenomics.
Dr Nhu Ngoc Le delivered an oral presentation titled “Prioritising New Antihypertensive Drug Targets and Unravelling Disease Modulation by Antihypertensive Drugs Using Mendelian Randomisation”. This is the largest study to investigate the effect of seventeen different antihypertensive drug classes on a wide range of cardiovascular, metabolic, and kidney diseases, using Mendelian randomisation framework. The findings highlight the potential protective effects of endothelin receptor antagonists, sGC stimulators, and PDE5 inhibitors against coronary artery disease, myocardial infarction, and ischemic stroke.
Dr Stefanie Lip presented "The Demographic Burden of Pharmacogenetic Prescribing: The Case for Panel Pharmacogenomic Testing to Ensure Equitable Healthcare." This study highlighted the potential for panel pharmacogenomic (PGx) testing to improve healthcare equity, especially for individuals from deprived areas who face a higher burden of polypharmacy, pharmacogenetic prescribing needs, and multimorbidity.
Mr Quoc Bao Tran Tran presented "Patterns of New Pharmacogenomic Drug Prescriptions and Socioeconomic Disparities in Glasgow: Insights from Longitudinal Data Analysis." This large-scale study identified significant socioeconomic disparities in PGx drug exposure among patients in Glasgow, with more deprived patients facing higher risks of being prescribed additional PGx drug classes. The findings underscore the need for further research into inequalities in access to PGx-guided therapy and the importance of incorporating socioeconomic factors into personalised medicine approaches.
The Pontecorvo research team would like to thank the SCMH Training & Awards Committee (TAAC) and NHS Education for Scotland for their support in funding their participation in this prestigious conference. This opportunity has been invaluable in enhancing our pharmacogenomic expertise, fostering collaborations, and advancing their careers.
First published: 12 November 2024
<< News